Last reviewed · How we verify

NCT05306158

Dual Use Approach Bias Training for Nicotine Addiction

Completed NA Last updated 27 March 2025
What this trial tests

NA trial testing CC+ECIG Condition in Tobacco Smoking in 107 participants. Completed in 30 November 2024.

Timeline
3 October 2022
Primary endpoint
30 September 2024
30 November 2024

Quick facts

Lead sponsorUniversity of Houston
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment107
Start date3 October 2022
Primary completion30 September 2024
Estimated completion30 November 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Houston

Who can join

18 and older, any sex, with Tobacco Smoking or Electronic Cigarette Use. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present project will evaluate the initial efficacy of approach bias retraining among dual combustible cigarette (CC) and electronic cigarette (ECIG) users. The study employs a randomized controlled design to follow 90 experienced dual CC/ECIG users motivated to quit nicotine as they engage in a self-guided quit attempt following approach bias retraining.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Study protocol for approach bias retraining for nicotine addiction among dual combustible and electronic cigarette users.
    Clausen B, Rinck M, Nizio P, Matoska CT, et al · · 2023 · PMID 36905980 · DOI 10.1016/j.cct.2023.107145

Verify or expand the search:

Other recruiting trials for Tobacco Smoking

Currently open trials in the same condition.

Other University of Houston trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05306158.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing